586353-04-0

Basic information

• Product Name: 4H-Indazol-4-one, 2,5,6,7-tetrahydro-2-(triphenylmethyl)-
• CAS NO: 586353-04-0
• Molecular Formula: C26H22N2O
• Molecular Weight: 378.473
• Mol File: 586353-04-0.mol

Chemical Properties

• CAS DataBase Reference: 4H-Indazol-4-one, 2,5,6,7-tetrahydro-2-(triphenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Indazol-4-one, 2,5,6,7-tetrahydro-2-(triphenylmethyl)-(586353-04-0)
• EPA Substance Registry System: 4H-Indazol-4-one, 2,5,6,7-tetrahydro-2-(triphenylmethyl)-(586353-04-0)

Safety Data

• Hazardous Substances Data: 586353-04-0(Hazardous Substances Data)

Usage

Physical appearance

white to off-white powder

Solubility

insoluble in water, soluble in organic solvents

Uses

building block for synthesis of biologically active compounds in pharmaceutical industry

Properties

potential antitumor and anticancer effects in preclinical studies

Potential applications

research and therapeutic contexts

Upstream product

• 499206-33-6 2,5,6,7-tetrahydro-4H-indazol-4-one 
• 76-83-5 trityl chloride 
• 504-02-9 1,3-cylohexanedione 
• 85302-07-4 2-(dimethylaminomethylene)cyclohexane-1,3-dione 
• 912259-10-0 1⁽²⁾,5,6,7-tetrahydro-4H-indazole-4-one 

Downstream Products

• 1031440-36-4 2-trityl-2,5,6,7-tetrahydro-indazol-4-one oxime 
• 586353-05-1 oxo-(4-oxo-2-trityl-4,5,6,7-tetrahydro-2H-indazol-5-yl)-acetic acid ethyl ester 

Relevant articles and documents

Mercaptan compound having HDAC6 (histone deacetylase 6) inhibitory activity and application thereof

The invention belongs to the technical field of medicines and relates to a mercaptan compound having an anti-tumor activity, in particular to a mercaptan compound containing a 6(7)-substituted-N-(6-decylhexyl)-pyrazolo[3,4-e] indazole-3-formamide fragment

Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators

There is an increasing amount of evidence to support that activation of the metabotropic glutamate receptor 4 (mGlu4 receptor), either with an orthosteric agonist or a positive allosteric modulator (PAM), provides impactful interventions in diseases such as Parkinson's disease, anxiety, and pain. mGlu4 PAMs may have several advantages over mGlu4 agonists for a number of reasons. As part of our efforts in identifying therapeutics for central nervous system (CNS) diseases such as Parkinson's disease, we have been focusing on metabotropic glutamate receptors. Herein we report our studies with a series of tricyclic thiazolopyrazoles as mGlu4 PAMs.

Benzodipyrazoles: A new class of potent CDK2 inhibitors

The synthesis and the preliminary expansion of this new class of CDK2 inhibitors are presented. The synthesis was accomplished using a solution-phase protocol amenable to rapid parallel expansion and suitable to be scaled-up in view of possible lead devel